TY - JOUR
T1 - The activity of commercial antimicrobials, and essential oils and ethanolic extracts of Olea europaea on Streptococcus agalactiae isolated from pregnant women
AU - Mukesi, Munyaradzi
AU - Iweriebor, Benson Chucks
AU - Obi, Larry C.
AU - Nwodo, Uchechukwu U.
AU - Moyo, Sylvester R.
AU - Okoh, Anthony I.
N1 - Funding Information:
The authors would like to express their gratitude to the National Research Fund (NRF) of South Africa and the National Commission of Research Science and Technology (NCRST), Namibia.
Funding Information:
The authors are grateful to the NRF, SA and NCRST, Namibia for funding the research.
Publisher Copyright:
© 2019 The Author(s).
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/30
Y1 - 2019/1/30
N2 - © 2019 The Author(s). Background: Streptococcus agalactiae also known as Group B Streptococcus (GBS) is a major cause of disease in pregnant women and new born babies where it causes early and late onset disease characterised by sepsis, pneumonia and meningitis. Ten to 37 % of pregnant women in the world are colonised with GBS while intrapartum antibiotic prophylaxis has led to significant reduction in early onset disease. The increase in drug resistant microorganisms has become a major threat. Development of vaccines is still in progress so there is need for new and safer alternatives to treatment. Methods: Benzyl penicillin, Ampicillin, Cefotaxime, Ceftriaxone, Levofloxacin, Erythromycin, Clindamycin, Linezolid, Vancomycin, Tetracycline and Cotrimoxazole, Olea europaea leaf extracts and essential oil were tested against GBS isolates from South Africa and Namibia. Results: The isolates showed 100% sensitivity to benzyl penicillin, ampicillin, ceftriaxone, levofloxacin, linezolid, vancomycin, O. europaea leaf extracts and essential oils. Only one isolate (0.6%) was resistant to cefotaxime and 23.4 and 10.4% were resistant to clindamycin and erythromycin respectively. Conclusion: GBS isolates showed sensitivity to O. europaea extracts at low minimum inhibitory concentrations. Β lactams are still the drugs of choice for treatment of GBS disease but O. europaea extracts potent as an alternative source of antimicrobials.
AB - © 2019 The Author(s). Background: Streptococcus agalactiae also known as Group B Streptococcus (GBS) is a major cause of disease in pregnant women and new born babies where it causes early and late onset disease characterised by sepsis, pneumonia and meningitis. Ten to 37 % of pregnant women in the world are colonised with GBS while intrapartum antibiotic prophylaxis has led to significant reduction in early onset disease. The increase in drug resistant microorganisms has become a major threat. Development of vaccines is still in progress so there is need for new and safer alternatives to treatment. Methods: Benzyl penicillin, Ampicillin, Cefotaxime, Ceftriaxone, Levofloxacin, Erythromycin, Clindamycin, Linezolid, Vancomycin, Tetracycline and Cotrimoxazole, Olea europaea leaf extracts and essential oil were tested against GBS isolates from South Africa and Namibia. Results: The isolates showed 100% sensitivity to benzyl penicillin, ampicillin, ceftriaxone, levofloxacin, linezolid, vancomycin, O. europaea leaf extracts and essential oils. Only one isolate (0.6%) was resistant to cefotaxime and 23.4 and 10.4% were resistant to clindamycin and erythromycin respectively. Conclusion: GBS isolates showed sensitivity to O. europaea extracts at low minimum inhibitory concentrations. Β lactams are still the drugs of choice for treatment of GBS disease but O. europaea extracts potent as an alternative source of antimicrobials.
KW - Antimicrobial
KW - Olea europaea
KW - Streptococcus agalactiae
KW - β Lactams
UR - http://www.scopus.com/inward/record.url?scp=85060846498&partnerID=8YFLogxK
U2 - 10.1186/s12906-019-2445-4
DO - 10.1186/s12906-019-2445-4
M3 - Article
C2 - 30700288
SN - 1472-6882
VL - 19
JO - BMC Complementary and Alternative Medicine
JF - BMC Complementary and Alternative Medicine
IS - 1
M1 - 34
ER -
